Low Molecular Fucoidan Research Articles

ガンに対する低分子化フコイダンを中心とした統合医療の臨床改善報告 ～第5 報

ガンに対する低分子化フコイダンを中心とした統合医療の臨床改善報告 ～第5 報

Clinical Improvement in Cancer Patients through Integrative Medicine Approach Mainly with Low-Molecular Fucoidan ~ The Six Report

Clinical Improvement in Cancer Patients through Integrative Medicine Approach Mainly with Low-Molecular Fucoidan ~ The Six Report

Clinical Improvement in Cancer Patients through Integrative Medicine Supplemented Mainly with Low-Molecular Fucoidan

Clinical Improvement in Cancer Patients through Integrative Medicine Supplemented Mainly with Low-Molecular Fucoidan

Low molecular fucoidan and its macromolecular complex with bee venom melittin

Low molecular weight (LMW) fucoidan, obtained by free radical depolymerization of high molecular polysaccharide extract of brown algae Hizikia fusiformis, was complexed with HPLC purified bee venom melittin. Water soluble form of the LMW fucoidan – melittin complex shows increased anti-inflammatory activity, inhibiting the production of nitric oxide in murine macrophage cell line Raw 264.7. The LMW fucoidan:melitin complex obtained in this study showed good biological activities, resulting in 2-fold reduction of the melittin toxicity. The fucoidan: melittin macromolecular complex obtained should be useful in future therapeutic applications.

Oral Single Dose Toxicity Study of Low Molecular Fucoidan in Mice

This study was conducted to obtain information of the oral dose toxicity of low molecular fucoidan (LMF) in male and female mice. In order to calculate 50% lethal dose (LD50) and approximate lethal dose (LD), test material was once orally administered to male and female ICR mice at dose levels of 2000, 1000, 500, 250, 125 and 0 (vehicle control) mg/kg (body wt.). The mortality and the changes on body weight, clinical signs, gross observation and organ weight and histopathology of principle organs were monitored 14 days after LMF treatment. We could not find any mortalities, clinical signs, body weight changes and gross findings. In addition, significant changes in the organ weight and histopathology of principal organs were not observed except for some sporadic findings. The results obtained in this study suggest that LMF may not be toxic in mice and may be therefore safe for clinical use. The LD50 and approximate LD in mice after single oral dose of LMF were considered over 2000 mg/kg in both female and male mice.